Affimed
Manufacturing · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Gottlieb-daimler-straße 2, Mannheim, Bad...Phone Number
+49 621560030Website
www.affimed.comRevenue
<$5 MillionStock Symbol
AFMDIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Affimed
Founded in 2000 and headquartered in Heidelberg, Baden-Wuerttemberg, Affimed is a clinical-stage immuno-oncology company developing therapies to treat cancer. The company platform provides to a specific patient population.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Affimed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Affimed is spiking on competitors!
Earning: See what the market has to say on Affimed recently announced quarterly report
Product Launch: Get notified when Affimed launches new products
Check if Affimed has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Affimed has new funding data
Congratulate Masked Content for being promoted to Masked Content at Affimed
Affimed, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Affimed had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Affimed as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Affimed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Affimed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Affimed.
Affimed financials insights
Gather financial insights about Affimed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$56M
2021
Debt
$30.4M
Affimed Tech Stack
A closer look at the technologies used by Affimed
Most Recent Scoops
Earnings
Earnings, Finance
Project
Affimed is progressing a study combining allo NK and AFM 13 for patients with refractory Hodgkin lymphoma, with clinical data from four cohorts to be presented at ASH 2024. Additionally, the company's AFM 28 program targeting CD 123 for relapsed/refractory AML will be featured in an oral presentation at ASH, with updated data from the ongoing phase one trial.
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Event
will present key clinical updates at the upcoming ASH 2024 conference in December, including an oral presentation on AFM 28 and preclinical data at a poster session. The company will also host a conference call on December 17th to provide a clinical update on AFM 24.
Events, Search, Medical Research, Pharmaceuticals
Project
will focus on response rate data in its December data disclosure for its ongoing trial, as progression-free survival (PFS) data are not yet mature. The company expects to see PFS data from over 40 patients, although response data may be available for slightly fewer patients due to potential dropouts.
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Project
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Affimed News & Media
Affimed Announces Filing for the Opening of Insolvency Proceedings
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE®) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research (AACR).Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking placeAffimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed b
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Affimed
Sign Up For FreeTo access detailed company insights
Founded in 2000 and headquartered in Heidelberg, Baden-Wuerttemberg, Affimed is a clinical-stage immuno-oncology company developing therapies to treat cancer. The company platform provides to a specific patient population.... Read More
